iiCON and the Liverpool School of Tropical Medicine
A £2.7 million Translational Development Fund launched in partnership with the Liverpool School of Tropical Medicine (LSTM).
Overview
The Translational Development Fund was launched in partnership with the Liverpool School of Tropical Medicine (LSTM) to support the development of diagnostics and treatments. We also joined the LSTM-led Infection Innovation Consortium (iiCON) to accelerate the discovery and development of new therapies and innovations.
About the Translational Development Fund
We are partnering with the Liverpool School of Tropical Medicine (LSTM) to launch a new £2.7 million Translational Development Fund. This fund will support the development of diagnostics and treatments to tackle emerging viral threats and neglected tropical diseases.
Who is the fund available to?
The fund will be available to all of LSTM’s partners, including research organisations in low-and-middle-income countries.
Infection Innovation Consortium (iiCON)
We have also joined the LSTM-led Infection Innovation Consortium (iiCON), alongside other core partners such as Unilever, Evotec, the Liverpool University Hospitals Foundation Trust, the University of Liverpool, and Infex Therapeutics. The aim of the £250 million programme is to accelerate the discovery and development of new therapies and innovations.
iiCON agreement
As part of this agreement, we have made our antibody humanisation platform available for iiCON and its partners to support the development of new potential treatments. The Translational Development Fund will also be available to iiCON and its collaborators.
Contact us
In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. If you would like your data to be removed, please email dataprivacy@lifearc.org.
Please see our Privacy Policy in relation to the personal data you submit to us through this page.
Related stories
-
News releases
LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases
Read more: LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases -
News releases
First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Read more: First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases -
News releases
New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
Read more: New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya